Xarelto Back On Track: J&J Answers "Complete Response" Letter And Files For Atrial Fibrillation
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Johnson & Johnson and Bayer HealthCare may gain a market advantage if regulators grant an approval with indications for both chronic and acute use of its anticoagulant rivaroxaban, based on regulatory filings the co-development partners announced Jan. 5.